Loengard Anna U
Known title: DirectorCIK: 0001952723
Loengard Anna U's purchase track record
How the stock did after each of Loengard Anna U's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since September 6, 2023
Stock higher 6 months later
50%
3 months: 50%
Median 6-month return
+104.0%
3 months: +18.9%
Beat the S&P 500
50%
median +94.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/13/2025 | CLOV | $69K | -4.2% | -21.8% | +7.3% |
| 5/16/2024 | CLOV | $26K | +184.8% | +229.8% | +12.3% |
| 3/14/2024 | CLOV | $110K | +42.1% | +282.1% | +8.6% |
| 9/6/2023 | CLOV | $14K | -28.2% | -39.4% | +14.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CLOV | ▲ Buy | Grant | 79,365 | $0 | 1/6/2026 | View on chart |
| CLOV | ▲ Buy | Open Market | 12,000 | $31K | 8/13/2025 | View on chart |
| CLOV | ▲ Buy | Open Market | 14,500 | $38K | 8/13/2025 | View on chart |
| CLOV | ▲ Buy | Grant | 60,975 | $0 | 1/6/2025 | View on chart |
| CLOV | ▲ Buy | Open Market | 10,000 | $9K | 5/17/2024 | View on chart |
| CLOV | ▲ Buy | Open Market | 15,600 | $15K | 5/16/2024 | View on chart |
| CLOV | ▲ Buy | Open Market | 1,485 | $1K | 5/16/2024 | View on chart |
| CLOV | ▲ Buy | Open Market | 137,000 | $100K | 3/14/2024 | View on chart |
| CLOV | ▲ Buy | Open Market | 13,625 | $10K | 3/14/2024 | View on chart |
| CLOV | ▲ Buy | Grant | 206,185 | $200K | 1/3/2024 | View on chart |
| CLOV | ▲ Buy | Open Market | 10,000 | $13K | 9/6/2023 | View on chart |
| CLOV | ▲ Buy | Open Market | 500 | $650 | 9/6/2023 | View on chart |
| CLOV | ▲ Buy | Open Market | 500 | $650 | 9/6/2023 | View on chart |
| CLOV | ▲ Buy | Grant | 176,991 | $0 | 1/3/2023 | View on chart |
| CLOV | ▲ Buy | Grant | 12,665 | $0 | 11/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Clover Health Gains After Earning 5-Star CMS Rating
Clover Health stock rose after the company secured a 5-star rating for its PPO plan from CMS for 2027. This top score supports the company's long-term outlook and may help attract new members. The news follows a period where the stock was trading near its 52-week high, reflecting positive market sentiment.
Clover Health Gains After Earning 5-Star CMS Rating. Clover Health stock rose after the company secured a 5-star rating for its PPO plan from CMS for 2027. This top score supports the company's long-term outlook and may help attract new members. The news follows a period where the stock was trading near its 52-week high, reflecting positive market sentiment.